Summary
Treatment with the oral Janus kinase (JAK) inhibitor tofacitinib was associated with an improvement in the signs and symptoms of rheumatoid arthritis (RA), physical function, and patient reported outcomes in RA patients with an inadequate response to tumor necrosis factor inhibitors (TNFi). The improved response was maintained over 24 months.
- Rheumatology Clinical Trials
- Rheumatoid Arthritis
- © 2012 MD Conference Express®
Tools
Short- and Long-Term Efficacy of Tofacitinib in the Treatment of Patients with RA and an Inadequate Response to TNF Inhibitors
Permalink:
Table of contents
Cited By...
- No citing articles found.